PapersFlow Research Brief
Multiple Myeloma Research and Treatments
Research Guide
What is Multiple Myeloma Research and Treatments?
Multiple Myeloma Research and Treatments is a field in hematology that studies the diagnosis, staging, treatment options, and molecular classification of multiple myeloma, including criteria from the International Myeloma Working Group, novel therapies such as proteasome inhibitors and immunomodulatory drugs, autologous transplantation, genomic abnormalities, and the bone marrow microenvironment's role in disease progression.
Research encompasses 89,297 works on multiple myeloma diagnosis, staging, and therapies. Key developments include updated diagnostic criteria and staging systems that correlate clinical features with patient outcomes. Consensus guidelines also define response assessment and minimal residual disease evaluation.
Topic Hierarchy
Research Sub-Topics
International Myeloma Working Group Criteria
Researchers refine diagnostic, response, and minimal residual disease assessment criteria for multiple myeloma through consensus updates. Validation studies test criteria against survival outcomes and new biomarkers.
Proteasome Inhibitors in Multiple Myeloma
Clinical trials evaluate bortezomib, carfilzomib, and ixazomib efficacy, resistance mechanisms, and combinations in relapsed/refractory disease. Studies explore proteasome biology in myeloma cell survival.
Immunomodulatory Drugs for Myeloma
Investigations focus on lenalidomide, pomalidomide, and apremilast mechanisms including cereblon binding, immune modulation, and anti-angiogenesis. Research addresses optimal sequencing and toxicity management.
Multiple Myeloma Genomic Abnormalities
Sequencing studies identify high-risk cytogenetic features like t(4;14), del(17p), and gain(1q) prevalence, prognostication, and therapeutic targeting. Single-cell genomics reveals clonal evolution.
Bone Marrow Microenvironment in Myeloma
Researchers study stromal cell, osteoclast, and immune interactions promoting myeloma growth, drug resistance, and bone disease. Novel therapies target microenvironmental pathways like RANKL and IL-6.
Why It Matters
Standardized diagnostic criteria from Rajkumar et al. (2014) in "International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma" enable consistent identification of multiple myeloma cases worldwide, improving clinical trial enrollment and patient management. The Durie-Salmon staging system by Durie and Salmon (1975) in "A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival" links myeloma cell mass to survival, guiding prognostic assessments in 71 patients. The International Staging System by Greipp et al. (2005) in "International Staging System for Multiple Myeloma" stratifies 10,750 untreated patients into risk groups using simple clinical and lab data, facilitating international comparisons and treatment decisions. Kumar et al. (2016) in "International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma" provide benchmarks for evaluating therapies like immunomodulatory drugs, supporting advancements in autologous transplantation outcomes.
Reading Guide
Where to Start
"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma" by Rajkumar et al. (2014) first, as it provides foundational diagnostic standards essential for understanding all subsequent staging and treatment research.
Key Papers Explained
Rajkumar et al. (2014) in "International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma" builds on Durie and Salmon (1975) in "A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival" by updating diagnostic thresholds informed by cell mass correlations; Greipp et al. (2005) in "International Staging System for Multiple Myeloma" simplifies this into albumin and beta-2 microglobulin-based stages from 10,750 patients; Kumar et al. (2016) in "International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma" extends these by defining response metrics compatible with novel therapies.
Paper Timeline
Most-cited paper highlighted in red. Papers ordered chronologically.
Advanced Directions
Current efforts focus on integrating minimal residual disease into staging per Kumar et al. (2016), alongside genomic abnormalities and bone marrow microenvironment studies referenced in the field description. No recent preprints or news available indicate ongoing refinements to International Myeloma Working Group criteria.
Papers at a Glance
| # | Paper | Year | Venue | Citations | Open Access |
|---|---|---|---|---|---|
| 1 | International Myeloma Working Group updated criteria for the d... | 2014 | The Lancet Oncology | 4.7K | ✓ |
| 2 | Selective inhibition of BET bromodomains | 2010 | Nature | 4.2K | ✓ |
| 3 | Docetaxel and Estramustine Compared with Mitoxantrone and Pred... | 2004 | New England Journal of... | 3.7K | ✓ |
| 4 | A unique clonal JAK2 mutation leading to constitutive signalli... | 2005 | Nature | 3.5K | ✕ |
| 5 | Prednisone plus cabazitaxel or mitoxantrone for metastatic cas... | 2010 | The Lancet | 3.2K | ✕ |
| 6 | A clinical staging system for multiple myeloma correlation of ... | 1975 | Cancer | 3.0K | ✕ |
| 7 | International Staging System for Multiple Myeloma | 2005 | Journal of Clinical On... | 2.9K | ✕ |
| 8 | International Myeloma Working Group consensus criteria for res... | 2016 | The Lancet Oncology | 2.8K | ✕ |
| 9 | BET Bromodomain Inhibition as a Therapeutic Strategy to Target... | 2011 | Cell | 2.8K | ✓ |
| 10 | Diagnosis and management of AML in adults: 2022 recommendation... | 2022 | Blood | 2.6K | ✓ |
Frequently Asked Questions
What are the updated criteria for diagnosing multiple myeloma?
Rajkumar et al. (2014) in "International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma" outline criteria based on biomarkers and clinical features for accurate diagnosis. These updates incorporate advancements in detecting clonal plasma cells and organ damage. The guidelines standardize identification across international settings.
How does the Durie-Salmon staging system work for multiple myeloma?
Durie and Salmon (1975) in "A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival" correlate myeloma cell mass, calculated from monoclonal immunoglobulin levels, with clinical features in 71 patients. The system uses bivariate and multivariate analyses to predict response and survival. Stages reflect tumor burden and guide treatment intensity.
What is the International Staging System for multiple myeloma?
Greipp et al. (2005) in "International Staging System for Multiple Myeloma" developed a simple system using serum albumin and beta-2 microglobulin levels from 10,750 untreated symptomatic patients across 17 institutions. It classifies patients into three stages for reliable prognostication. The system supports international patient stratification in trials.
How is response and minimal residual disease assessed in multiple myeloma?
Kumar et al. (2016) in "International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma" define uniform criteria for treatment response and MRD detection. These include flow cytometry and molecular methods for sensitive evaluation. The standards aid in monitoring novel therapies like proteasome inhibitors.
What role do novel therapies play in multiple myeloma treatment?
Research covers novel therapies including proteasome inhibitors and immunomodulatory drugs alongside autologous transplantation. International Myeloma Working Group criteria integrate these into diagnosis and response assessment. Genomic abnormalities and bone marrow microenvironment influence therapy selection.
Open Research Questions
- ? How can minimal residual disease assessment be standardized across diverse patient populations to predict long-term relapse?
- ? What genomic abnormalities most strongly predict resistance to proteasome inhibitors and immunomodulatory drugs?
- ? How does the bone marrow microenvironment contribute to disease progression beyond current staging systems?
- ? Which refinements to the International Staging System improve prognostic accuracy for high-risk multiple myeloma?
Recent Trends
The field includes 89,297 works with emphasis on International Myeloma Working Group criteria, as in Rajkumar et al. and Kumar et al. (2016), alongside Durie-Salmon (1975) and Greipp et al. (2005) staging systems.
2014No growth rate data over 5 years or recent preprints/news available.
Research Multiple Myeloma Research and Treatments with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Multiple Myeloma Research and Treatments with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers